90 related articles for article (PubMed ID: 27793200)
1. Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy.
Gomez-Millan J; Pajares B; Perez-Villa L; Carnero A; Alvarez M; De Luque V; Rivas F; Trigo JM; Toledo MD; Alba E; Medina JA
BMC Cancer; 2016 Oct; 16(1):829. PubMed ID: 27793200
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy.
Franceschini D; Paiar F; Saieva C; Bonomo P; Agresti B; Meattini I; Greto D; Mangoni M; Meacci F; Loi M; Zei G; Livi L; Biti G
Radiol Med; 2016 Mar; 121(3):229-37. PubMed ID: 26403512
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy.
Homma A; Furuta Y; Oridate N; Nakano Y; Kohashi G; Yagi K; Nagahashi T; Yagi K; Nagahashi T; Fukuda S; Inoue K; Inuyama Y
Clin Cancer Res; 1999 Apr; 5(4):801-6. PubMed ID: 10213215
[TBL] [Abstract][Full Text] [Related]
4. DNA repair pathways to regulate response to chemoradiotherapy in patients with locally advanced head and neck cancer.
Cirauqui B; Margelí M; Quiroga V; Quer A; Karachaliou N; Chaib I; Ramírez JL; Muñoz A; Pollán C; Planas I; Drozdowsky A; Rosell R
Tumour Biol; 2016 Oct; 37(10):13435-13443. PubMed ID: 27465548
[TBL] [Abstract][Full Text] [Related]
5. Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
Franco P; Potenza I; Schena M; Riva G; Pecorari G; Garzino Demo P; Fasolis M; Moretto F; Garzaro M; Di Muzio J; Melano M; Airoldi M; Ragona R; Rampino M; Ricardi U
Anticancer Res; 2015 Nov; 35(11):6247-54. PubMed ID: 26504058
[TBL] [Abstract][Full Text] [Related]
6. p53 expression in concurrent chemoradiotherapy with docetaxel for head and neck squamous cell carcinoma.
Oridate N; Homma A; Higuchi E; Suzuki F; Hatakeyama H; Mizumachi T; Furusawa J; Taki S; Furuta Y; Fukuda S
Auris Nasus Larynx; 2009 Feb; 36(1):57-63. PubMed ID: 18472237
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of bone or cartilage invasion of locally advanced head and neck cancers.
Do L; Syed N; Puthawala A; Azawi S; Williams R; Vora N
Am J Clin Oncol; 2010 Dec; 33(6):591-4. PubMed ID: 20065851
[TBL] [Abstract][Full Text] [Related]
8. Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94).
Ghadjar P; Pöttgen C; Joos D; Hayoz S; Baumann M; Bodis S; Budach W; Studer G; Stromberger C; Zimmermann F; Kaul D; Plasswilm L; Olze H; Bernier J; Wust P; Aebersold DM; Budach V
Strahlenther Onkol; 2016 Aug; 192(8):552-60. PubMed ID: 27323753
[TBL] [Abstract][Full Text] [Related]
9. Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkers.
Lin P; Min M; Lee M; Holloway L; Forstner D; Bray V; Fowler A
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):801-811. PubMed ID: 28004135
[TBL] [Abstract][Full Text] [Related]
10. Induction of CD44 variant 9-expressing cancer stem cells might attenuate the efficacy of chemoradioselection and Worsens the prognosis of patients with advanced head and neck cancer.
Aso T; Matsuo M; Kiyohara H; Taguchi K; Rikimaru F; Shimokawa M; Segawa Y; Higaki Y; Umeno H; Nakashima T; Masuda M
PLoS One; 2015; 10(3):e0116596. PubMed ID: 25751671
[TBL] [Abstract][Full Text] [Related]
11. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
12. Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies.
Stein AP; Swick AD; Smith MA; Blitzer GC; Yang RZ; Saha S; Harari PM; Lambert PF; Liu CZ; Kimple RJ
Cancer Med; 2015 May; 4(5):699-712. PubMed ID: 25619980
[TBL] [Abstract][Full Text] [Related]
13. Can adaptive threshold-based metabolic tumor volume (MTV) and lean body mass corrected standard uptake value (SUL) predict prognosis in head and neck cancer patients treated with definitive radiotherapy/chemoradiotherapy?
Akagunduz OO; Savas R; Yalman D; Kocacelebi K; Esassolak M
Nucl Med Biol; 2015 Nov; 42(11):899-904. PubMed ID: 26275933
[TBL] [Abstract][Full Text] [Related]
14. Multimodality management of high-risk head and neck basal cell carcinoma requiring free-flap reconstruction.
Burch MB; Chung TK; Rosenthal EL; Schmalbach CE
Otolaryngol Head Neck Surg; 2015 May; 152(5):868-73. PubMed ID: 25805638
[TBL] [Abstract][Full Text] [Related]
15. Which is the most suitable lymph node predictor for overall survival after primary surgery of head and neck cancer: pN, the number or the ratio of positive lymph nodes, or log odds?
Yildiz MM; Petersen I; Eigendorff E; Schlattmann P; Guntinas-Lichius O
J Cancer Res Clin Oncol; 2016 Apr; 142(4):885-93. PubMed ID: 26711282
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implications of hemoglobin levels before and after surgery as well as before and after radiochemotherapy for head and neck tumors.
Reichel O; Panzer M; Wimmer C; Dühmke E; Kastenbauer E; Suckfüll M
Eur Arch Otorhinolaryngol; 2003 May; 260(5):248-53. PubMed ID: 12750913
[TBL] [Abstract][Full Text] [Related]
17. The impact of body mass index and nuclear β-catenin on survival in locally advanced rectal cancer treated with preoperative radiochemotherapy.
Gomez-Millan J; Queipo MI; Del Mar Delgado M; Perez-Villa L; Roman A; De la Portilla F; Torres E; De Luque V; Bayo E; Medina JA
J Surg Oncol; 2017 Mar; 115(3):301-306. PubMed ID: 28335081
[TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study.
Driessen CM; de Boer JP; Gelderblom H; Rasch CR; de Jong MA; Verbist BM; Melchers WJ; Tesselaar ME; van der Graaf WT; Kaanders JH; van Herpen CM
Eur J Cancer; 2016 Jan; 52():77-84. PubMed ID: 26655558
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
Wen B; Zhang L; Wang C; Huang R; Peng H; Zhang T; Dong J; Xiao W; Zeng Z; Liu M; Gao Y
Radiat Oncol; 2015 Jun; 10():124. PubMed ID: 26040453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
